Argentina Advances Health Technology Evaluation Agency
Argentina’s national government confirmed it is moving forward with the creation of the National Agency for Health Technology Financing Evaluation, known as Anefits, to review high-cost treatments for public and private healthcare systems. lavoz.com.ar reported that while officials have not set a specific launch date for the body, the project continues to advance following its initial announcement in March 2025. The agency’s development coincides with the federal government’s withdrawal from funding certain expensive medications, a shift that has already prompted pharmaceutical companies like Roche to establish local offices and sign direct coverage agreements with provincial authorities.
High-Cost Drug Pressures and Budget Strains
Financiers in Argentina face mounting pressure as high-priced medications consume an increasingly large share of health budgets. Alfredo Gamietea, president of Osdepym, stated during the Argentine Health Congress organized by the Civil Association of Integrated Medical Activities that just two percent of patients account for half of that organization’s medication budget. Industry actors report that medications historically accounted for roughly 14 percent of healthcare spending, but that figure now exceeds 40 percent. This rapid growth strains resources available for other medical services, technological investments, and healthcare personnel salaries.
Scientific Criteria Versus Judicial Mandates
Anefits will evaluate treatments, medications, and health technologies using scientific criteria regarding safety, efficacy, and cost-benefit ratios. A committee of specialists will dictate which therapies warrant funding by health insurance providers, prepaid medical plans, or the state. This evaluation framework aims to replace decisions driven solely by individual medical indications or judicial injunctions. Currently, many patients secure coverage for rejected treatments through legal petitions, and the agency is intended to serve as a technical reference point to decrease such litigation by establishing more uniform standards.
Scope of Impact on Specialty Treatments
The regulatory focus centers specifically on very high-value therapies used for oncology, rare diseases, and autoimmune conditions. Consequently, the impact on everyday prescription drug sales in standard pharmacies remains limited. The agency addresses treatments that represent a small fraction of patients while absorbing a substantial portion of national healthcare resources.
Questions About Implementation Timelines
Uncertainty persists regarding when Anefits will officially open its doors and begin issuing binding coverage evaluations. Officials have not established a definitive calendar for the agency’s operational rollout, leaving the industry waiting for further details on how the new technical protocols will interact with existing legal mandates.